EBS Q2 2025 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$446M

Q2 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$141M-44.7% YoY

Gross Profit

$61M43.1% margin

Operating Income

$2M1.1% margin

Net Income

-$12M-8.5% margin

EPS (Diluted)

$-0.22

QoQ Revenue Growth

-36.6%

Cash Flow

Operating Cash Flow

$106M

Free Cash Flow

$104M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$881M

Stockholders' Equity

$536M

Cash & Equivalents

$271M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$141M	$255M	-44.7%
Gross Profit	$61M	-$66M	+192.7%
Operating Income	$2M	-$204M	+100.8%
Net Income	-$12M	-$283M	+95.8%

Revenue Segments

Product

$130M92%

Contracts and Grants

$11M8%